top of page
NEWS & BLOGS

FDA Proposes Major Updates to Infant Formula Standards: What Manufacturers Need to Know in 2026

43 minutes ago
4 min read

The U.S. Food and Drug Administration (FDA) is taking another step toward modernizing infant formula regulations.

On October 29, 2026, the agency announced a proposed rule that would update or reaffirm nutrient specifications for eight nutrients required in infant formula. This is the first phase of a broader review of the 30 nutrients currently required under U.S. regulations.

At the same time, the FDA is increasing transparency around infant formula testing, publishing results on chemical contaminants and continuing its monitoring of potential food safety risks.

For infant formula manufacturers, ingredient suppliers, and companies planning to enter the U.S. market, these developments highlight the importance of maintaining strong formulation, manufacturing, and quality control systems.

1. What Is the FDA Proposing to Change?

Under current FDA regulations, infant formula sold in the United States must meet specifications for 30 required nutrients.

The October 2026 proposed rule focuses on eight nutrients:

Four nutrients with proposed specification changes:

  • Iodine: The proposed minimum would increase from 5 to 15 micrograms per 100 kcal, while the maximum would decrease from 75 to 50 micrograms.

  • Manganese: The proposed minimum would decrease from 5 to 1 microgram per 100 kcal, with a new maximum of 50 micrograms.

  • Vitamin A: The measurement unit would change from International Units (IU) to micrograms of retinol activity equivalents (RAE). The proposed range would be 70–120 micrograms RAE per 100 kcal.

  • Vitamin D: The measurement unit would change from IU to micrograms. The proposed range would increase from the current equivalent of 1–2.5 micrograms to 2–3 micrograms per 100 kcal.

Four nutrients for which the FDA proposes retaining existing specifications:

  • Chloride

  • Potassium

  • Selenium

  • Sodium

These proposals reflect the FDA's review of scientific evidence concerning infant nutritional needs and safe intake levels.

Importantly, the proposal does not mean that existing infant formulas are suddenly noncompliant or unsafe. The FDA describes this initiative as a proactive effort to bring regulatory standards in line with current scientific understanding.

2. Why Is the FDA Reviewing Infant Formula Nutrients?

The FDA's comprehensive review is organized into three phases.

The first phase addresses iodine, manganese, selenium, sodium, potassium, chloride, vitamin A, and vitamin D.

The remaining nutrients will be evaluated in subsequent phases.

The FDA is also requesting input on nutrients that are commonly added by manufacturers but are not currently required, including:

  • Docosahexaenoic acid (DHA)

  • Arachidonic acid (ARA)

  • L-carnitine

These nutrients are being considered because of their potential contributions to infant development and nutrition.

The agency intends to consolidate the resulting changes into one comprehensive final rule after the review process and public comment periods.

For manufacturers, this means nutrient compliance should not be treated as a static requirement. Formulation strategies may need to evolve as scientific evidence and regulatory standards develop.

3. FDA Is Also Increasing Its Focus on Chemical Contaminants

Nutrient composition is only one part of infant formula oversight.

On October 29, 2026, the FDA also highlighted its infant formula testing program and released additional testing information.

The agency monitors infant formula for various chemical contaminants, including:

  • Heavy metals: arsenic, lead, cadmium, and mercury

  • PFAS (per- and polyfluoroalkyl substances)

  • Pesticides

  • Phthalates

  • Other chemical substances

The FDA's published testing results indicate that heavy metal levels were generally very low or undetectable in the sampled products.

In a 2026 supplemental survey involving 104 powdered infant formula samples, the agency reported that pesticides were not detected in 309 pesticide-sample results, including testing for glyphosate and glufosinate. Most of the PFAS compounds tested were also not detected.

These findings are encouraging, but they should be interpreted within the scope of the specific sampling programs. They do not establish that every infant formula product is free of contaminants.

The FDA continues to monitor potential risks and may take action when unsafe contamination levels are identified.

4. Microbiological Safety Remains Critical

Chemical contaminant testing is not the only area of concern.

Infant formula manufacturers must also address microbiological hazards, particularly Cronobacter and Salmonella.

FDA regulations establish a zero-tolerance threshold for these bacteria in infant formula.

Recent public health events have also highlighted the importance of supplier oversight. In July 2026, the FDA called on the infant formula industry to strengthen supply chain controls following investigations involving infant botulism outbreaks associated with powdered formula and contamination concerns involving ingredient suppliers.

This reinforces an important point: finished-product testing alone cannot replace effective preventive controls and supplier qualification.

Manufacturers need to understand the risks associated with raw materials, ingredient suppliers, manufacturing environments, and finished products.

5. What Should Infant Formula Manufacturers Prepare For?

For companies manufacturing infant formula for the U.S. market, these developments provide an opportunity to review existing regulatory and quality systems.

Formulation and Nutrient Specifications

Manufacturers should review current formulations against the proposed nutrient specifications and assess whether potential changes could affect product composition.

Ingredient and Supplier Qualification

Ingredient quality and supplier oversight are essential, particularly for ingredients with microbiological or chemical contamination risks.

Testing and Quality Controls

A comprehensive quality program should address nutrient verification, chemical contaminant testing, microbiological hazards, and appropriate manufacturing controls.

Labeling and Documentation

If the proposed nutrient changes are finalized, manufacturers may need to update formulation documentation, nutrient declarations, and product labeling.

Regulatory Change Management

Companies should monitor FDA rulemaking and evaluate how future requirements may affect manufacturing, sourcing, and product commercialization.

6. What Is the Timeline?

The October 29 announcement is a proposed rule, not a final regulation.

The FDA is accepting public comments and will consider stakeholder input before finalizing the requirements.

The agency has proposed a compliance period of three years from the effective date of the final comprehensive rule to allow manufacturers to reformulate and relabel products as necessary.

The FDA is also continuing its phased review of the remaining required nutrients.

Manufacturers should therefore distinguish between current regulatory obligations and proposed future requirements when planning compliance activities.

Conclusion: Infant Formula Compliance Requires Continuous Oversight

The FDA's 2026 actions demonstrate that infant formula regulation involves more than meeting a list of nutrient specifications.

Product formulation, ingredient quality, supplier oversight, contaminant monitoring, microbiological controls, and labeling all contribute to regulatory readiness.

For companies entering or operating in the U.S. infant formula market, staying ahead of regulatory changes is essential to maintaining product quality and market readiness.



For inquiries or expert assistance, please contact us today.




CONTACT US

Office: 1-909-493-3276

 
 
bottom of page